Ag270 clinical
WebDec 1, 2024 · We have developed a first-in-class, highly potent, orally bioavailable MAT2A inhibitor, AG-270, which is currently under investigation in a phase 1 clinical trial (ClinicalTrials.gov NCT03435250). AG-270 selectively inhibits the growth of HCT116 MTAP-/- cells compared to HCT116 MTAP+/+ cells in vitro and in vivo . WebOct 27, 2024 · AG-270 is a first-in-class, oral, potent, reversible inhibitor of methionine adenosyltransferase 2A (MAT2A), the key enzyme responsible for SAM synthesis. …
Ag270 clinical
Did you know?
WebAbout this study The purpose of this study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) when given daily by … WebSubjects whose tumor tissue has lost the MTAP protein may be considered for future enrollment into a Phase 1 clinical study of an experimental drug, AG-270, that is designed to inhibit the growth of tumors lacking this protein. Identification of the loss of MTAP will rely solely on the evaluation of archival tumor tissue samples by IHC.
WebOct 27, 2024 · Clinical Trial’ Using Patient Derived Xenograft Models . Anti-tumor activity observed in a variety of models, with examples of regressions / tumor stasis. Efficacy in ~70 . MTAP-deleted PDX models. N=3 per model; established tumors treated at 200 mpk AG-270 QD . 0. 50. 100. 150. 200. Tumor Volume (mm. 3) NSCLC (SCC) PDX Model. 0. … WebApr 8, 2024 · We demonstrate that potent MAT2A inhibitors substantially reduce SAM levels in cancer cells and selectively block proliferation of MTAP -null cells both in tissue culture …
WebApr 12, 2024 · Mirati Therapeutics, Inc. announced initial preclinical results evaluating its investigational synthetic lethal PRMT5 inhibitor in methylthioadenosine phosphorylase (MTAP)-deleted cancer models. Mirati's internally discovered PRMT5 compound is the first to specifically target the PRMT5/methylthioadenosine (MTA) complex.
WebFeb 1, 2024 · AG-270 in Combination with Docetaxel a. Be ≥18 years of age; a. Have histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that has been treated with no more than 2 prior lines of cytotoxic chemotherapy in the setting of metastatic (Stage 4) disease.
WebAug 15, 2024 · We have developed a first-in-class small molecule inhibitor of MAT2A, AG-270, currently in a phase 1 clinical study (ClinicalTrials.gov NCT03435250) for the treatment of patients with solid tumors ... scotch ice ball makerWebLaboratory specialty areas at Mayo Clinic include: Anatomic Pathology. Clinical Biochemistry and Immunology. Clinical Core Laboratory Services. Clinical Microbiology. … scotch ice cubes traysWebAssessing Clinical Symptom Patterns Several types of scales have been developed to evalu-ate clinical problems. There are three types of scales that address problems in … pregnancy 2 months in hindiWebApr 8, 2024 · These data supported progressing AG-270 into current clinical studies (ClinicalTrials.gov NCT03435250). Authors: Konteatis, Zenon [1]; Search DOE PAGES for author "Konteatis, Zenon" Search DOE PAGES for ORCID "0000-0002-5421-4907" Search orcid.org for ORCID "0000-0002-5421-4907" pregnancy 2 month dietWebOct 27, 2024 · expectations for its and its collaborator’s preclinical, clinical and commercial advancement of its drug development programsincluding AG-270; the potential benefits … scotch hutchinsonWebFeb 19, 2024 · Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss. The safety and scientific validity of this study is the responsibility of the … scotch hydrofuge waterproofWebAg-270 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ag-270, 1 is phase 1 (1 open). ... ag 270, ag270, mat2a inhibitor ag-270 Drug Target(s) : MAT2A NCIT ID : C153180 References. 1. National Cancer Institute. NCI Thesaurus Version 18.11d. ... scotch hyper resistant